Résumé
The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug resistance after treatment. This article has been explained separately from the ALK genetic background, the detection method, the treatment of the three generations of ALK inhibitors and the strategy after drug resistance. It is desire to have reference value and reference meaning for clinical work. .
Sujets)
Humains , Kinase du lymphome anaplasique , Carcinome pulmonaire non à petites cellules , Traitement médicamenteux , Génétique , Résistance aux médicaments antinéoplasiques , Génétique , Fusion de gènes , Tumeurs du poumon , Traitement médicamenteux , Génétique , Inhibiteurs de protéines kinases , Pharmacologie , Utilisations thérapeutiques , Récepteurs à activité tyrosine kinase , GénétiqueRésumé
The theory of tumor immunity has gone through more than a century of exploration and shown remarkable clinical efficacy. Therapy based on targeting immune checkpoints,especially anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibody monotherapy,has made significant progress in the treatment of advanced lung cancer.Consequently,the discovery of new immune checkpoints has be-come an area of interest.Additionally,combined immunotherapy is expected to be the future direction of immunotherapy.However, at this stage,immunotherapy has not yet resulted in widespread benefit.Identifying immune resistance mechanisms will further pro-mote individualized treatment.